Table 1. Patient characteristics of elite suppressors, chronic progressors, and acutely infected individuals.

Patient	Year of diagnosis	Sampling date	Duration of infectiona	Plasma viral load (RNA copies/ml)	CD4 count (cells/µl)
Elite Suppressors
ES2	1986	5/04	18 years	<50	383
ES3	1991	3/04	13 years	<50	677
ES4	1996	8/04	8 years	<50	837
ES7	1994	1/05	11 years	<50	1,125
ES8	2003	6/04, 9/04	1 year	<50	458
ES9	1999	3/04, 8/04	5 years	<50	800
ES10	2002	3/04	2 years	<50	900
Chronic Progressors
C61	1999	9/04	5 years	19,100	1,261
C62	1998	9/04	6 years	33,300	481
C93	2001	3/05	4 years	47,270	402
C94	1999	2/05	6 years	22,898	351
C96	2001	3/05	4 years	12,500	400
C98	2004	3/05	1 year	17,838	426
C109	2002	5/05	3 years	61,000	222
Acute Infection
502	–	–	19 days	31,622,777	306
503	–	–	17 days	588,844	531
504	–	–	32 days	2,691,535	152
506	–	–	43 days	467,735	341
508	–	–	26 days	389,045	266
510	–	–	16 days	1,584,893	581
512	–	–	25 days	3,388,442	745
514	–	–	26 days	676,083	291
516	–	–	51 days	295,121	371
517	–	–	38 days	87,096	588
518	–	–	15 days	21,379,621	226
519	–	–	22 days	1,819,701	322
520	–	–	40 days	257,040	512
522	–	–	21 days	3,235,937	583
523	–	–	28 days	173,780	273
526	–	–	26 days	100,000	205
527	–	–	21 days	134,896	538
528	–	–	16 days	12,022,644	438
529	–	–	19 days	28,840,315	537
530	–	–	30 days	6,456,542	469

^aTime of infection expressed in approximate years for ES and CP patients from diagnosis to sampling. Time of infection for acute infection samples estimated by 14 days after the onset of acute seroconversion symptoms or identification of high risk transmission event, and sampling was conducted <4 weeks post-presentation and initiation of HAART.